TIDMEKF

RNS Number : 3139L

EKF Diagnostics Holdings PLC

12 January 2021

This announcement contains inside information

for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

Trading update

Full year performance expected to be comfortably ahead of upgraded market consensus

Q1 2021 performance to materially exceed management expectations

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, confirms that continued strong trading will result in the performance for the year ending 31 December 2020 being comfortably ahead of already upgraded market expectations.

Trading in the core business in the final quarter has continued to improve significantly and ongoing demand for the PrimeStore MTM COVID-19 sample collection device remained strong through to the end of the year and will continue to do so into the first quarter of 2021. Following the payment of the dividend of GBP4.6m in December 2020, the earlier investment of GBP3.8m in Trellus Health Limited, and the proceeds from the sale of Renalytix AI plc shares of GBP7.7m, the Company's net cash at 31 December 2020 was in excess of GBP21m. The Company will pay a dividend again in December 2021 and expects to implement a progressive dividend policy.

With continued strong performance in the core business and a number of indicative orders for PrimeStore MTM for the first quarter 2021 that are likely to be realised, the Board is confident that performance for the first quarter of 2021 will be materially ahead of current management expectations, and the first quarter of 2020.

The persons responsible for arranging the release of this Announcement on behalf of the Company are Julian Baines, CEO, and Richard Evans, FD and COO respectively.

 
     EKF Diagnostics Holdings plc                                        www.ekfdiagnostics.com 
     Christopher Mills, Non-executive Chairman                        Tel: +44 (0) 29 2071 0570 
     Julian Baines, CEO 
     Richard Evans, FD & COO 
 
     N+1 Singer                                                              Tel: 020 7496 3000 
     Aubrey Powell / George Tzimas (Corporate 
      Finance) 
      Tom Salvesen (Corporate Broking) 
 
     Walbrook PR Limited                        Tel: +44 (0) 20 7933 8780 or ekf@walbrookpr.com 
     Paul McManus / Lianne Cawthorne                   Mob: +44 (0) 7980 541 893 / +44 (0) 7584 
                                                                                        391 303 
 
 

About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.

About PrimeStore MTM

Global demand for the PrimeStore MTM sample containment device has increased significantly due to COVID-19. The device was invented in 2006 in preparation for a worldwide pandemic and is designed to de-activate pathogen rapidly and stabilise the RNA for up to four weeks with no requirement for cold storage. This approach also allows samples to be tested by a greater number of laboratories, as the handling risks for the deactivated virus are reduced.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTFLFVTLFILLIL

(END) Dow Jones Newswires

January 12, 2021 02:00 ET (07:00 GMT)

Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Ekf Diagnostics Charts.
Ekf Diagnostics (LSE:EKF)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Ekf Diagnostics Charts.